Home » News » Awards & Advancement » CeNeRx completes $4.85 million financing round

CeNeRx completes $4.85 million financing round

Monday, December 12, 2011

CeNeRx BioPharma has completed a $4.85 million financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners, Pappas Ventures and Omega Funds all participated in the financing. CeNeRx plans to use the proceeds to complete its ongoing phase II trial of the improved formulation of its novel antidepressant TriRima as monotherapy in treatment resistant depression, as well as to support advancement of its pipeline for a variety of CNS disorders.

“Our phase II trial of TriRima in treatment resistant depression is proceeding very well and these funds will primarily be used to help complete the study,” said Barry Brand, chief executive officer of CeNeRx.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!